PPK Group announced that it has partnered with Xefco Pty Ltd to commence immediate local production of anti-viral, antibacterial face masks using Xefco’s developed technology.
An independent study by the Peter Doherty Institute for Infection and Immunity has shown that the technology is able to inactivate SARSCoV-2 (the virus associated with COVID-19) in as little as five minutes.
Researchers exposed textile treated with the technology to known infectious concentrations of SARS-CoV-2 for incremental periods of time before extracting and measuring the remaining infectious virus titre. The results showed that the treated textiles deactivated the SARS-CoV-2 virus by 97.79% within five minutes and 99.95% within 15 minutes with no infectious virus detectable on the textiles after 30 minutes.
The functional mask technology is based on an ultra-thin / nano-scale coating of 99.95% pure copper, applied to the surface of the fabrics using a vapour deposition process. The key components of this technology were developed by Xefco in collaboration with Deakin University’s Institute for Frontier Materials. While highly visible, the application does not change the feel, breathability or weight of the underlying fabric, and the technology can be applied to a broad range of materials.
The two companies, via a joint venture, will also look to licence the technology to international manufacturers around the world.
Following PPK’s core technology investments into Boron Nitride Nanotube Manufacturing Technology in particular, this new initiative in the healthcare space is consistent with PPK’s technology commercialisation strategy and focus on nanotechnology breakthroughs with global application in large markets.
Executive Chairman of PPK, Robin Levison noted: “PPK is always on the look-out for new opportunities to back breakthrough technologies, particularly in the nanotechnology space and with the involvement of leading Universities like Deakin, that are ready to be brought to market on an international scale. The chance to combine the manufacturing assets of PPK’s Mask Innovation business with leading science developed by Xefco in conjunction with Deakin University represents a tremendous commercialisation opportunity with global application. It is also an incredibly timely one and yields a likelihood of making a very practical and immediate difference in combating one of the great healthcare issues of our time.”